The genomic and transcriptional landscape of primary central nervous system lymphoma
Josefine Radke, Naveed Ishaque, Randi Koll, Zuguang Gu, Elisa Schumann, Lina Sieverling, Sebastian Uhrig, Daniel Hübschmann, Umut H. Toprak, Cristina López, Xavier Pastor Hostench, Simone Borgoni, Dilafruz Juraeva, Fabienne Pritsch, Nagarajan Paramasivam, Gnana Prakash Balasubramanian, Matthias Schlesner, Shashwat Sahay, Marc A. Weniger, Debora Pehl, Helena Radbruch, Anja Osterloh, Agnieszka Korfel, Martin Misch, Julia Onken, Katharina Faust, Peter Vajkoczy, Dag Moskopp, Yawen Wang, Andreas Jödicke, Lorenz Trümper, Ioannis Anagnostopoulos, Dido Lenze, Ralf Küppers, Michael Hummel, Clemens A. Schmitt, Otmar D. Wiestler, Stephan Wolf, Andreas Unterberg, Roland Eils, Christel Herold‐Mende, Benedikt Brors, Reiner Siebert, Susanne Wagner, Andrea Haake, Julia Richter, Gesine Richter, Chris Lawerenz, Jules N. A. Kerssemakers, Christina Jaeger-Schmidt, Ingrid Scholz, Anke Bergmann, Christoph Borst, Friederike Braulke, Birgit Burkhardt, Alexander Claviez, Martin Dreyling, Sonja Eberth, Hermann Einsele, Norbert Frickhofen, Siegfried Haas, Martin‐Leo Hansmann, Dennis Karsch, Nicole Klepl, Michael Kneba, Jasmin Lisfeld, Luisa Mantovani‐Löffler, Marius Rohde, German Ott, Christina Stadler, Peter Staib, Stephan Stilgenbauer, Thorsten Zenz, Dieter Kube, Wolfram Klapper, Ulrike Kostezka, Peter Möller, Andreas Rosenwald, Monika Szczepanowski, Ole Ammerpohl, Sietse Aukema, Vera Binder, Arndt Borkhardt, Jessica I. Hoell, Ellen Leich, Peter Lichter, Inga Nagel, Jordan Pischimariov, Bernhard Radlwimmer, Philip Rosenstiel, Markus B. SchilhabelNature Communications2022 · DOI
By integrating whole-genome and transcriptome sequencing of 51 patients, researchers have mapped the most comprehensive molecular landscape to date of Primary Central Nervous System Lymphoma (PCNSL). The study reveals that PCNSL is a distinct clinical and biological entity from systemic lymphomas, driven by a "perfect storm" of high-frequency mutations in the MYD88/CD79B pathways, massive CDKN2A deletions, and unique immune-evasion tactics.
What Problem Does This Paper Address?
Primary Central Nervous System Lymphoma (PCNSL) is a rare, aggressive form of non-Hodgkin lymphoma that develops strictly within the brain, eyes, or spinal cord. While it looks like systemic Diffuse Large B-cell Lymphoma (DLBCL) under a microscope, it behaves very differently and often has a poorer prognosis.
Until now, we haven't fully understood the "molecular engine" that drives PCNSL or why it remains sequestered in the CNS. Previous studies were often limited to "exome-only" sequencing (looking only at protein-coding regions) or small sample sizes. This paper aims to fill that gap by using a multi-omic approach to identify the specific genetic drivers, mutational signatures, and transcriptional profiles that define PCNSL.
Methods
The researchers performed a deep dive into 51 CNS lymphoma cases using two primary "lenses":
Whole-Genome Sequencing (WGS): To capture mutations not just in genes, but in the regulatory "dark matter" of the genome, as well as structural rearrangements (like translocations).
Transcriptome Sequencing (RNA-seq): To see which genes are actually being "turned on" or "off."
They compared these results against 75 cases of systemic lymphomas (Follicular Lymphoma and DLBCL) from the ICGC MMML-Seq cohort. Key bioinformatics tools included LymphGen for genetic subtyping, IntOGen for driver discovery, and TelomereHunter to estimate telomere maintenance—a critical factor in cancer cell immortality.
Datasets
Primary Cohort: 51 adult patients with CNS lymphoma (including 42 immunocompetent PCNSL cases and a few secondary or EBV-positive cases).
Comparison Cohort: Data from the ICGC MMML-Seq project, including 39 Follicular Lymphoma (FL) and 36 systemic DLBCL cases.
Controls: Non-malignant brain tissue (frontal lobe) and matched peripheral blood samples to filter out "normal" genetic variation.
Key Insights and Ideas
The "MCD" Identity: The vast majority of PCNSL cases belong to the "MCD" genetic subtype (characterized by MYD88 and CD79B mutations). However, PCNSL is an extreme version of this subtype, showing much higher mutation frequencies than systemic MCD-DLBCL.
Immune Stealth Mode: PCNSL exhibits significantly more focal deletions in the HLA-D (6p21) locus. By deleting these genes, the tumor effectively removes the "red flags" that would normally allow T-cells to recognize and kill it.
The Mitotic Clock: The study found an enrichment of mutational signature SBS1, which is linked to the number of times a cell has divided. This suggests that PCNSL cells are proliferating at an incredibly high rate before they are even diagnosed.
TERT Overdrive: PCNSL shows significantly higher expression of the TERT gene (which maintains telomeres) compared to systemic counterparts. Interestingly, they didn't find the usual TERT promoter mutations, suggesting PCNSL uses different, perhaps epigenetic, mechanisms to keep its telomeres from shortening.
Transcriptional Fingerprint: Despite looking like systemic DLBCL, PCNSL has a unique RNA expression profile, particularly high expression of IGHM, which can be used to clearly distinguish it from lymphomas outside the brain.
Key Results
Hallmark Mutations: Recurrent mutations were found in MYD88 L265P (67%), CD79B (63%), and PIM1 (70%).
Copy Number Changes: Deletions of the tumor suppressor CDKN2A were found in a staggering 83% of cases.
Structural Variants: The study identified "enhancer hijacking" events, where genomic rearrangements move powerful enhancers near oncogenes like BCL6, driving their over-expression.
Pathways: The most heavily hit pathways were JAK-STAT, NFkB, and B-cell receptor signaling, providing a clear rationale for testing inhibitors targeting these specific nodes (like BTK inhibitors) in PCNSL.
Limitations and Future Work
While this is a landmark study, the authors note a few areas for further exploration:
EBV+ Cases: The small number of Epstein-Barr Virus-positive cases (n=5) appeared genetically very different, lacking the typical MYD88 hotspots. These require a dedicated, larger study.
Clinical Correlation: While the paper identifies many "targetable" alterations, it does not provide long-term clinical trial data to prove that targeting these specific mutations improves patient survival.
The "Why" of CNS Tropism: While the paper describes the landscape of the tumor, the exact reason why these specific mutations lead to a tumor that only grows in the brain remains a complex biological question for future functional studies.
Summary updated
Abstract
Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell lymphomas (DLBCLs) confined to the central nervous system (CNS). Molecular drivers of PCNSL have not been fully elucidated. Here, we profile and compare the whole-genome and transcriptome landscape of 51 CNS lymphomas (CNSL) to 39 follicular lymphoma and 36 DLBCL cases outside the CNS. We find recurrent mutations in JAK-STAT, NFkB, and B-cell receptor signaling pathways, including hallmark mutations in MYD88 L265P (67%) and CD79B (63%), and CDKN2A deletions (83%). PCNSLs exhibit significantly more focal deletions of HLA-D (6p21) locus as a potential mechanism of immune evasion. Mutational signatures correlating with DNA replication and mitosis are significantly enriched in PCNSL. TERT gene expression is significantly higher in PCNSL compared to activated B-cell (ABC)-DLBCL. Transcriptome analysis clearly distinguishes PCNSL and systemic DLBCL into distinct molecular subtypes. Epstein-Barr virus (EBV)+ CNSL cases lack recurrent mutational hotspots apart from IG and HLA-DRB loci. We show that PCNSL can be clearly distinguished from DLBCL, having distinct expression profiles, IG expression and translocation patterns, as well as specific combinations of genetic alterations.
BibTeX
@inproceedings{radke2022genomic,
author = {Josefine Radke and Naveed Ishaque and Randi Koll and Zuguang Gu and Elisa Schumann and Lina Sieverling and Sebastian Uhrig and Daniel Hübschmann and Umut H. Toprak and Cristina López and Xavier Pastor Hostench and Simone Borgoni and Dilafruz Juraeva and Fabienne Pritsch and Nagarajan Paramasivam and Gnana Prakash Balasubramanian and Matthias Schlesner and Shashwat Sahay and Marc A. Weniger and Debora Pehl and Helena Radbruch and Anja Osterloh and Agnieszka Korfel and Martin Misch and Julia Onken and Katharina Faust and Peter Vajkoczy and Dag Moskopp and Yawen Wang and Andreas Jödicke and Lorenz Trümper and Ioannis Anagnostopoulos and Dido Lenze and Ralf Küppers and Michael Hummel and Clemens A. Schmitt and Otmar D. Wiestler and Stephan Wolf and Andreas Unterberg and Roland Eils and Christel Herold‐Mende and Benedikt Brors and Reiner Siebert and Susanne Wagner and Andrea Haake and Julia Richter and Gesine Richter and Roland Eils and Chris Lawerenz and Roland Eils and Jules N. A. Kerssemakers and Christina Jaeger-Schmidt and Ingrid Scholz and Anke Bergmann and Christoph Borst and Friederike Braulke and Birgit Burkhardt and Alexander Claviez and Martin Dreyling and Sonja Eberth and Hermann Einsele and Norbert Frickhofen and Siegfried Haas and Martin‐Leo Hansmann and Dennis Karsch and Nicole Klepl and Michael Kneba and Jasmin Lisfeld and Luisa Mantovani‐Löffler and Marius Rohde and German Ott and Christina Stadler and Peter Staib and Stephan Stilgenbauer and Thorsten Zenz and Martin‐Leo Hansmann and Dieter Kube and Siegfried Haas and Wolfram Klapper and Ulrike Kostezka and Peter Möller and Andreas Rosenwald and German Ott and Monika Szczepanowski and Ole Ammerpohl and Sietse Aukema and Vera Binder and Arndt Borkhardt and Andrea Haake and Jessica I. Hoell and Ellen Leich and Peter Lichter and Cristina López and Inga Nagel and Jordan Pischimariov and Bernhard Radlwimmer and Julia Richter and Philip Rosenstiel and Andreas Rosenwald and Markus B. Schilhabel},
title = {{The genomic and transcriptional landscape of primary central nervous system lymphoma}},
booktitle = {Nature Communications},
year = {2022},
doi = {10.1038/s41467-022-30050-y},
}